Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Chugai, Taisho To Seek Approval For Co-Developed Drug

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical and Taisho Pharmaceutical, both of Japan, plan to submit their eledecalcitol drug for approval in the country. Phase III trials of the vitamin D derivative have been positive, besting a Teijin competitor in comparison trials for treating fractures related to osteoporosis. Chugai, majority-owned by Roche, discovered the drug and is considering foreign trials, according to a spokesman. (Click here for more

You may also be interested in...



Chugai To Deploy Chiome’s MAb Generation Technology

TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel